APRIL Overview
Molecule Name
Tumor necrosis factor ligand superfamily member 13
Synonyms
APRIL,TNFSF13,TALL-2,TRDL-1,CD256,TALL2,ZTNF2
Drug Development Progress
Drugs in Clinical Trials29
Approved Drugs2
Highest Development StageApproved
Target Synonym
Tumor Necrosis Factor Ligand 7B，CD256 Antigen，TNLG7B，CD256，TNF- and APOL-related leukocyte expressed ligand 2，TNFSF13，TNF-related death ligand 1，ZTNF2，TALL-2，APRIL，Tumor necrosis factor ligand superfamily member 13，TNF Superfamily Member 13，Tumor Necrosis Factor (Ligand) Superfamily， Member 13，TRDL-1，TALL2，Tumor Necrosis Factor Superfamily Member 13，Tumor Necrosis Factor-Like Protein ZTNF2，UNQ383/PRO715，A Proliferation-Inducing Ligand，Tumor Necrosis Factor-Related Death Ligand-1
Background
APRIL(a proliferation-inducing ligand) is also known as Tumor necrosis factor ligand superfamily member 13, TALL-2, TRDL-1, CD256, TNFSF13, cytokine that binds to TNFRSF13B/TACI and to TNFRSF17/BCMA. APRIL is a cytokine of the tumor necrosis factor family associated mainly with hematologic malignancies. The closely related TNF family ligands B cell activation factor (BAFF) and a proliferation-inducing ligand (APRIL) serve in the generation and maintenance of mature B-lymphocytes. Both BAFF and APRIL assemble as homotrimers that bind and activate several receptors that they partially share. BAFF-APRIL heteromers of different stoichiometries have distinct receptor-binding properties and activities. In addition, expression of APRIL was regulated by miR-145 in GC cells.
APRIL Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Zigakibart | BION-1301; FUB523; FUB-523 | Phase 3 Clinical | Aduro Biotech Inc | Glomerulonephritis, IGA; Multiple Myeloma; Proteinuria | Details |
| Povetacicept | ALPN-303; ALPN 30x | Phase 3 Clinical | Alpine Immune Sciences Inc | Anemia, Hemolytic, Autoimmune; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Cytopenia; Glomerulonephritis; Glomerulonephritis, IGA; Glomerulonephritis, Membranous; Inflammation; Lupus Erythematosus, Systemic; Lupus Nephritis; Myasthenia Gravis; Nephrosis; Purpura, Thrombocytopenic, Idiopathic; Sjogren's Syndrome | Details |
| CLYM-116 | CLYM116; MIL116 | Phase 2 Clinical | Beijing Mabworks Biotech Co Ltd | Glomerulonephritis, IGA | Details |
| IM-21 | IM21; IM-21 | Phase 1 Clinical | Imunopharm Technology Co Ltd | Multiple Myeloma | Details |
| anti-BCMA CAR T-cell therapy (Sichuan University) | Phase 1 Clinical | Sichuan University | Multiple Myeloma | Details | |
| dual anti-CS-1/anti-BCMA CAR T-cell therapy (Wuhan Sian Medical Technology) | Phase 1 Clinical | Wuhan Sian Biotechnology Co Ltd | Multiple Myeloma | Details | |
| dual anti-BCMA/anti-CD38 CAR T-cell therapy (Shengyan Pharmaceutical Technology/Tongji Medical College) | Phase 1 Clinical | Tongji Medical College | Multiple Myeloma | Details | |
| BCMA-CS1 cCAR T-cell therapy | Phase 1 Clinical | iCell Gene Therapeutics LLC | Multiple Myeloma | Details | |
| anti-BCMA CAR T-cell therapy (National Cancer Institute) | Phase 1 Clinical | National Cancer Institute | Multiple Myeloma | Details | |
| anti-BCMA CAR T-cell therapy (Kite) | FHVH33-CD8BBZ | Phase 1 Clinical | Teneobio Inc | Multiple Myeloma | Details |
| anti-BCMA CAR T-cell therapy (Yake Biotechnology/Zhejiang University) | Phase 1 Clinical | Shanghai Yake Biotechnology Co Ltd | Multiple Myeloma | Details | |
| CBG-002 | CBG-002 | Phase 1 Clinical | Carbiogene Therapeutics Co Ltd | Multiple Myeloma | Details |
| BCMA-CD19 cCAR | Phase 1 Clinical | iCell Gene Therapeutics LLC | Lupus Erythematosus, Systemic; Lupus Nephritis; Multiple Myeloma; Neuromyelitis Optica; Rejection of organ transplantation; Waldenstrom Macroglobulinemia | Details | |
| SSS-68 | SSS68; SSS-68 | Phase 1 Clinical | Shenyang Sunshine Pharmaceutical Co Ltd | Glomerulonephritis, IGA | Details |
| GenSci-136 | GenSci136 | Phase 1 Clinical | Changchun GeneScience Pharmaceuticals Co Ltd | Autoimmune Diseases; Glomerulonephritis, IGA; Lupus Erythematosus, Systemic; Myasthenia Gravis; Sjogren's Syndrome | Details |
| JADE-001 | JADE-001; JADE001; PR030; PR-030; JADE101; JADE-101 | Phase 1 Clinical | Paragon Therapeutics Inc | Glomerulonephritis, IGA | Details |
| KD-6005 | KD-6005; KD6005 | Phase 1 Clinical | Shanghai Celgen Bio-Pharmaceutical Co Ltd, Shanghai Kanda Bio-Technology Co Ltd | Arthritis, Rheumatoid | Details |
| Anti-BCMA CAR T-cell therapy (Actavis/Eugia Pharma) | Phase 1 Clinical | Actavis Inc, Eugia Pharma Specialities Ltd | Multiple Myeloma | Details | |
| anti-TriPRIL CAR T-cell therapy（Massachusetts General Hospital） | Phase 1 Clinical | Massachusetts General Hospital | Multiple Myeloma | Details | |
| Aritinercept | AUR-200; AUR200 | Phase 1 Clinical | Thunderbolt Pharma Inc | Autoimmune Diseases | Details |
| RO-7297089 | RO-7297089; AFM-26; RG-6296 | Phase 1 Clinical | Genentech Inc | Multiple Myeloma | Details |
| APRIL CAR-T Cell therapy (Yake Biotechnology) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Multiple Myeloma | Details | |
| Anti-BCMA CAR T-cell therapy (Huazhong University of Science and Technology) | Clinical | Huazhong University Of Science And Technology | Multiple Myeloma | Details | |
| anti-BMCA CAR NK-cell therapy (Hangzhou Cheetah Cell Therapeutics/Zhejiang University) | Clinical | Zhejiang University | Multiple Myeloma | Details | |
| anti-BCMA CAR T-cell therapy engineered to express anti-IL6 scFv and IL1RA (Celledit) | Clinical | Celledit Llc | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| anti-BCMA CAR T-cell therapy (Shanghai GeneChem) | Clinical | Shanghai Genechem Co Ltd | Multiple Myeloma | Details | |
| anti-BCMA/NKG2DL/FAP TCR T-cell therapy (Guangdong VitaLife) | Clinical | Guangdong Vitalife Biotechnology Co Ltd | Multiple Myeloma | Details | |
| bispecific anti-CD19/anti-BCMA CAR T-cell therapy (Shanghai Hrain Biotechnology) | HRAIN-002 | Clinical | Hrain Biotechnology Co Ltd | Multiple Myeloma | Details |
| BCMA-UCART | BCMA-UCART | Clinical | BRL Medicine Inc | Multiple Myeloma | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Telitacicept | RCT-18; RCT18; RC-18; RC18 | Approved | 泰爱, Tai’ai | Mainland China | Lupus Erythematosus, Systemic | RemeGen Co Ltd | 2021-03-09 | Arthritis, Rheumatoid; Eye Diseases; Glomerulonephritis, IGA; Hepatitis, Autoimmune; Immunoglobulin G4-Related Disease; Lung Diseases, Interstitial; Lupus Erythematosus, Systemic; Lupus Nephritis; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Myasthenia Gravis; Nephrosis; Neuromyelitis Optica; Sjogren's Syndrome | Details | |
| Sibeprenlimab | VIS-649 | Approved | Visterra Inc | Voyxact | United States | Glomerulonephritis, IGA | Otsuka Pharmaceutical Co Ltd | 2025-11-25 | Glomerulonephritis; Glomerulonephritis, IGA; Sjogren's Syndrome | Details |